

Supplementary

Table S1 Treatment outcomes and objective response rate in patients with *de novo* T790M mutation (n=8)

Response	Mutation type					Total
	Exon19 + T790M	L858R + T790M	L858R + T790M + other	T790M	G719X + T790M	
CR	1	0	0	0	0	1
PR	0	1	0	0	0	1
SD	2	0	1	0	2	5
PD	0	0	0	1	0	1
					ORR	25%

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate.

Table S2 *EGFR* mutation types identified at initial biopsy and rebiopsy, among patients with repeated biopsies (n=57)

<i>EGFR</i> mutation(s) detected at second biopsy, n	<i>EGFR</i> mutation(s) detected at initial biopsy, n									Total
	Wild type	Del19	Del19 and T790M	L858R	L858R and T790M	L858R and other mutation	T790M and G719X	Other	Unknown	
Wild type	0	3	0	1	0	0	0	0	0	4
Del19	0	18	1	0	0	0	0	0	1	20
Del19 and T790M	0	13	0	0	0	0	0	0	0	13
L858R	0	0	0	7	1	3	0	0	1	12
L858R and T790M	0	0	0	2	0	1	0	0	0	3
L858R and other mutation	0	0	0	0	0	2	0	0	0	2
T790M	0	1	0	0	0	0	0	0	0	1
T790M and G719X	0	0	0	0	0	0	1	0	0	1
Other	0	0	0	0	0	0	0	1	0	1
Total	0	35	1	10	1	6	1	1	2	57

EGFR, epidermal growth factor receptor.

Table S3 Subsequent treatments after progression on first-line afatinib (n=138)

Treatment	Patients, n (%)
Pemetrexed	65 (47.1)
Osimertinib	21 (15.2)
Gemcitabine	16 (11.6)
Cisplatin	7 (5.1)
Olmotinib	6 (4.3)
Gefitinib	4 (2.9)
Afatinib	3 (2.2)
Nivolumab	2 (1.4)
Etoposide	1 (0.7)
Crizotinib	1 (0.7)
Other	12 (8.7)